linjc16/ctgov huggingface dataset:
Wearable Robotic Functional Assistance for Stroke Rehabilitation

Study Overview
=================
Brief Summary
-----------------
This study aims to evaluate the effectiveness of using the myomo e100 wearable robotic rehabilitation system for increasing functional independence and long term rehabilitation of chronic stroke victims with a hemiparetic upper extremity.

Detailed Description
-----------------
This is a case controlled study for evaluation of the effectiveness of using the myomo e100 wearable robotic rehabilitation for upper arm therapy following stroke. The intervention for the study will be for the control group- 6-8 weeks of therapeutic exercise and functional training for a total of 18 hours of intervention, or the case group- 6-8 weeks of therapeutic exercise and functional training with the use of the AJB for a total of 18 hours of intervention. Each session will be one hour in length. The length of the study and length of each session is per standard rehabilitation protocol that has been well documented in previous studies as well as the pilot study regarding the AJB. A pre and post test with a 3 month follow up of all measures will be included in the study. Study procedures will focus on performing functional tasks using the e100.

Official Title
-----------------
Wearable Robotic Functional Assistance for Stroke Rehabilitation

Conditions
-----------------
CVA (Cerebrovascular Accident)

Intervention / Treatment
-----------------
* Device: myomo e100 neurorobotic elbow brace


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Medically Stable Cognitive Awareness Weakness in upper arm Over 1 year post CVA not engaged in any other upper arm therapies Exclusion Criteria: Rashes, open wounds or skin sensitivity on arm Very high elbow tone (arm rigid in flexion or extension)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: myomo e100 neurorobotic elbow brace|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Motor Activity Log |  |  | 
| Fugl-Meyer Upper Arm Function |  |  | 
| Wolf Motor Function |  |  | 
| SF-36 QOL Survey |  |  | 
| Range of Motion |  |  | 
| Muscle Strength Test |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Robotics, Rehabilitation, Arm, Stroke, Weakness, Outpatient, Chronic
Penumbra Imaging Collaborative Study (PICS)

Study Overview
=================
Brief Summary
-----------------
The primary aim of this study are to gather data on the real world experience of the Penumbra System and to determine if there is a correlate between the imaging-defined size of the ischemic penumbra at admission and patient outcome in patients already treated by the System. This will be accomplished by the collection of all available admission imaging data along with patient clinical and functional outcome results at 90-day follow-up to determine if a positive association exists between these variables. A secondary aim is to collect and summarize the 90-day functional outcome data for the purpose of sample size estimation for a potential randomized concurrent controlled trial. This will be accomplished by collecting the data on 90-day modified Rankin Scores (mRS) and all cause mortality.

Official Title
-----------------
Penumbra Imaging Collaborative Study (PICS): A Multicenter Trial to Assess Outcome of Patients Revascularized by the Penumbra™ System

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Device: Penumbra System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients who signed informed consent and revascularized by the Penumbra™ System in accordance to the Instruction For Use are eligible for this study.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Penumbra System|Mechanical Thrombectomy in acute stroke|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients with an imaging-defined ischemic penumbra at admission that warrants revascularization by the Penumbra System. |  | Admission | 
| Proportion of patients with successful revascularization of the occluded target vessel as defined by a TIMI score of 2 or 3 following use of the Penumbra System. |  | Post-Procedure | 
| The proportion of patients with a modified Rankin Score (mRS) of ≤2 at 90 days post-procedure. |  | 90-Days Post-Procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neurological status as defined by the National Institute of Health Stroke Scale (NIHSS) scores at Admission and Discharge. |  | Admission and Discharge | 
| Incidence of intracranial hemorrhage. |  | 24-Hours Post-Procedure | 
| Incidence of device-related serious adverse events. |  | During the Procedure | 
| All cause mortality at 90 days post-procedure. |  | 90-Days Post-Procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Penumbra System, Mechanical Thrombectomy, Ischemic Stroke, Intervention, Neurovascular, Thrombus, Imaging, Ischemic Penumbra, Functional Outcome
Cohort as Part of Undergraduate Medical Studies at the University of Sherbrooke

Study Overview
=================
Brief Summary
-----------------
The main goals of this project are to support the research training of undergraduate medical students at the University de Sherbrooke and promote planning of health services a better knowledge of the prevalence, social, and geographic distribution of public health issues in several regions in Quebec. To meet the objectives of the project, a population-based prospective study linked to several regions in Quebec public health surveys is proposed. Monitoring and data collection will be provided by 3rd year undergraduate medical students at University de Sherbrooke through telephone interviews. The research themes will be proposed by various researchers affiliated with the University de Sherbrooke. They will be selected yearly by an internal scientific committee and included in the questionnaires administered by the students.

Official Title
-----------------
Cohort as Part of Undergraduate Medical Studies at the University of Sherbrooke

Conditions
-----------------
Public Health

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Participants will have been diagnosed with covid-19 between November 2020 and May 2021; Place of residence: province of Quebec. Exclusion criteria : - Unfit adults.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Estrie CIUSSS<br>Subjects from the Estrie's Integrated Health and Social Services Centre | Other: No intervention<br>* No intervention<br>|
| Saguenay-Lac-Saint-Jean CIUSSS<br>Subjects from the Saguenay-Lac-Saint-Jean's Integrated Health and Social Services Centres | Other: No intervention<br>* No intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Health questionnaire | General health questionnaire including questions about lifestyle, access to health services, comorbidities, mental health, alcohol and drugs consumption. Additional questions regarding more specific themes (Lyme disease, medical aid in dying, COVID-19, etc.) will be added or adapted yearly. Most of the questions are individually based on previously accepted or previously used questionnaires and thus, the health questionnaire used in this project does not include a specific scale of measurement for each subjects. | Once a year through study completion. |
The Headache Inducing Effects of Cilostazol on Migraine Patients

Study Overview
=================
Brief Summary
-----------------
We will use Cilostazol as a tool to investigate its headache inducing effects in migraine patients.

Official Title
-----------------
The Headache Inducing Effects of Cilostazol on Migraine Patients

Conditions
-----------------
Migraine

Intervention / Treatment
-----------------
* Drug: Cilostazol
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with migraine without aura according to the IHS criteria from 2004. Healthy besides migraine Exclusion Criteria: Tension-type headache more than 3 days per month Other types of primary headaches Pregnancy History of vascular diseases or psychiatric diseases.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Cilostazol<br>Capsule of Cilostazol 200 mg are taken orally on each study day | Drug: Cilostazol<br> <br> * Other names: Pletal;|
| Placebo Comparator: Placebo<br>A capsule of placebo containing starch are taken orally on each study day. | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The incidens of headache or migraine after adminstration of Cilostazol in migraine patients compared to placebo. | Rectruitment of 14 patients will be done during April and May. Experiments will be carried out in May and June. Each experiment day takes 1½ hour. Data analysis will be done in June and July. Final data will be presented within 6 months. | Outcome measure will be done within 3 month. Final data will be presented within 6 months |
Surgical Management of Giant Hepatic Hemangioma

Study Overview
=================
Brief Summary
-----------------
Hepatic hemangiomas are the commonest benign mesenchymal lesions of the liver. Most of these lesions are asymptomatic. Giant hepatic hemangiomas (GHH) (> 10 cm) are often symptomatic and require surgical intervention. This study aimed to describe the clinical findings, risk factors, diagnostic approach and management of GHH.

Detailed Description
-----------------
Hepatic hemangiomas are the most common benign tumors of the liver with the incidence of 0.4 to 20% . They are most often discovered incidentally on imaging studies. Typical hemangiomas usually do not increase in size over time and therefore are unlikely to cause symptoms. Giant hepatic hemangiomas (GHH) are defined as hemangiomas larger than 5 cm . They are usually responsible for overt clinical symptoms and complications consisting, most often, of upper abdominal pain, hemorrhage, biliary compression, or a consumptive coagulopathy that may require prompt surgical intervention or other treatments . Management of liver hemangiomas ranges from close observation to surgery depending upon the site, size and symptoms . It is widely accepted that intervention is indicated only for symptomatic hemangiomas. Surgical resection is indicated in patients with abdominal complaints or complications, or when diagnosis remains inconclusive. The ideal surgical treatment for GHH is still controversial. Enucleation is the preferred surgical method based on the existing literature. In this study, we report our 17-year experience of clinical management of GHH.

Official Title
-----------------
Surgical Management of Giant Hepatic Hemangioma: a 10-year Single Center Experience

Conditions
-----------------
Liver Angioma

Intervention / Treatment
-----------------
* Procedure: hepatectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Radiological diagnosis of geant liver hamangioma. Exclusion Criteria: Radiological diagnosis of liver hemangioma less than 10cm.

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| churgery of geant liver hemangioma<br> | Procedure: hepatectomy<br>* liver resection taking over the liver hemangioma<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of patient getting good result after surgery | patient asymptomatic after surgery or not | 1 year |
Revisiting Survey Investigating Why Patients Are Not Receiving Home Anti-convulsant Medication Prior to Surgery/or Procedure Involving General Anesthesia

Study Overview
=================
Brief Summary
-----------------
Children with seizure disorder face unique challenges during the perioperative period. Fasting, sleep-deprivation, and missed doses of medications while patients are required to have nothing per mouth (NPO) are a few factors that decrease the seizure threshold. The incidence of seizures in this population is unknown but correlated with patient's underlying condition and missed doses of anti-convulsant. Previous work has determined this is not a unique problem. The investigators initially found compliance extremely poor at 60%. The investigators have made improvement to about 80% compliance through various interventions: education of nursing, availability of anticonvulsant intravenous dosing alternatives, and re-wording the hospital NPO policy. The investigators feel that a new, more focused, survey will help identify, perioperative reasons for non-compliance on part of the parents. This information will be utilized to guide further interventions aimed at improving compliance.

Conditions
-----------------
Seizures

Intervention / Treatment
-----------------
* Other: Survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: We plan to include all children 0-18 years of age on anticonvulsant(s) for seizure disorder. Exclusion Criteria: None.

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Seizure disorder<br>Patients that are on medications for seizure disorder. | Other: Survey<br>* Families complete survey to measure medication compliance.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anticonvuslant compliance | Patients/parents will be asked to complete a questionnaire about whether they took their anticonvulsant the morning of surgery and if not, why not. | 1 Day |
Functional Genomics of Rare Genetic Diseases: Realization of Innovative Tools With High Diagnostic Power

Study Overview
=================
Brief Summary
-----------------
The project aims to improve the understanding of a significant group of rare diseases both from a genetic/diagnostic and clinical/experimental point of view and aims to develop one or more diagnostic protocols. The study will be conducted through the application of complementary experimental strategies, ranging from the clinical, genetic and molecular characterization of the pathology to the search for rare variants and the development of cellular disease models.

Detailed Description
-----------------
Clinical evaluation of patients and relatives High throughput analysis of genetic variants in genome exomes Genotype-phenotype association testing Identification of genetic risk variants for rare diseases

Official Title
-----------------
Functional Genomics of Rare Genetic Diseases: Realization of Innovative Tools With High Diagnostic Power

Conditions
-----------------
Rare Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients affected by: SLA, Incontinentia Pigmenti type II, Rett Syndrome, Paget Disease, Pompe Disease, Immunodeficiency, Centromeric instability and Facial anomalies, Cortical malformations and malignant epileptic encephalopathies Exclusion Criteria: none
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cases<br>Patients with rare disease | |
| controls<br>Healthy parents and relatives | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of genetic variants responsible for rare diseases | Analysis of exome sequencing data; annotation of genetic variants; selection of variants present in cases and absent in controls | Two years |
Home-based Massage by Caregivers for Dementia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the effects of manual massage on improving behavioral and psychological symptoms of dementia and sense of burden among caregivers.

Detailed Description
-----------------
A total of 40 patients with dementia and their family caregivers will be included and randomly allocated to experiment (n=20) or control group (n=20). The experiment and control group will receive whole body manual massage and placebo intervention (30 minutes once per week for 8 continuous weeks), respectively.

Official Title
-----------------
Effects of Manual Massage on Improving Behavioral and Psychological Symptoms of Dementia and Sense of Burden Among Caregivers

Conditions
-----------------
Dementia, Massage, Burden

Intervention / Treatment
-----------------
* Other: Home-based massage by caregivers for dementia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over 65 years old, diagnosed with dementia, agitation or depression, irregular massage and exercise habits. Exclusion Criteria: Those who have open wounds, inflammation, infection, burns and scalds, artificial blood vessels in the hands, or diagnosed as inappropriate for massage in the near future, the severity of symptoms affects the study participants.

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: experimental group<br>receive whole body manual massage | Other: Home-based massage by caregivers for dementia<br>* A total of 40 patients with dementia and their family caregivers will be included and randomly allocated to experiment (n=20) or control group (n=20). The experiment and control group will receive whole body manual massage and placebo intervention (30 minutes once per week for 8 continuous weeks), respectively.<br>|
| No Intervention: control group<br>After experiment, receive whole body manual massage | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change agitation | Cohen-Mansfield Agitation Inventory (CMAI) | before , during and after 8-weeks massage training interventions | 
| change depression | Cornell Scale for Depression in Dementia (CSDD) | before , during and after 8-weeks massage training interventions | 
| change stress | Perceived Stress Scale(PSS) | before , during and after 8-weeks massage training interventions |
Colour Doppler Flow Imaging in Lacrimal Gland Lesions

Study Overview
=================
Brief Summary
-----------------
Retrospective medical charts and medical imaging files review of patients suffering from lacrimal fossa lesions who underwent ocular ultrasonography with color flow doppler imaging.

Official Title
-----------------
Usefulness of Colour Doppler Flow Imaging in the Management of Lacrimal Gland Lesions

Conditions
-----------------
Lacrimal Tumor

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients suffering from lacrimal fossa tumor Orbital ultrasonography performed, including doppler flow imaging Histopathological characterization of the tumor obtained after surgical removal Exclusion Criteria: Absence of histopathological characterization Absence of documented ultrasound doppler flow imaging

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pulsed wave doppler resistance index in tumor vascularization |  | 1 week |